Skip to main content

Erasca, Inc.

For the period ended Mar 31, 2025. Filed May 13, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 13, 2025

ERAS$14.41+8.6%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Financial Statements (Unaudited)Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024

Item 1. Financial Statements.

Condensed Consolidated Balance Sheets

(In thousands, except share and par value amounts)

March 31,December 31,
20252024
Assets
Current assets:
Cash and cash equivalents$70,482$67,739
Short-term marketable securities234,103230,570
Prepaid expenses and other current assets10,03210,484
Total current assets314,617308,793
Long-term marketable securities106,492142,164
Property and equipment, net15,58716,321
Operating lease assets31,52532,218
Restricted cash408408
Other assets2,6152,622
Total assets$471,244$502,526
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$2,262$468
Accrued expenses and other current liabilities18,41826,308
Operating lease liabilities4,7914,619
Total current liabilities25,47131,395
Operating lease liabilities, net of current portion46,02047,270
Other liabilities251362
Total liabilities71,74279,027
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.0001 par value; 80,000,000 shares authorized at March 31, 2025 and December 31, 2024; no shares issued and outstanding at March 31, 2025 and December 31, 2024——
Common stock, $0.0001 par value; 800,000,000 shares authorized at March 31, 2025 and December 31, 2024; 283,265,716 and 283,218,344 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively2828
Additional paid-in capital1,197,4751,190,729
Accumulated other comprehensive income628405
Accumulated deficit(798,629)(767,663)
Total stockholders' equity399,502423,499
Total liabilities and stockholders' equity$471,244$502,526

Condensed Consolidated Statements of Operationsand Comprehensive Loss

(In thousands, except share and per share amounts)

Three Months Ended March 31,
20252024
Operating expenses:
Research and development$25,969$28,574
General and administrative9,66110,277
Total operating expenses35,63038,851
Loss from operations(35,630)(38,851)
Other income (expense)
Interest income4,7403,900
Other expense, net(76)(66)
Total other income (expense), net4,6643,834
Net loss$(30,966)$(35,017)
Net loss per share, basic and diluted$(0.11)$(0.23)
Weighted-average shares of common stock used in computing net loss per share, basic and diluted283,260,289151,161,741
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities, net223(287)
Comprehensive loss$(30,743)$(35,304)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.